NEW YORK, June 5, 2026, 07:05 (ET)
- Solid Biosciences was last seen at $7.24, up about 6%. This was before the Nasdaq opened for regular trading.
- H.C. Wainwright lifted its price target on Solid to $25 from $20 on June 3. The broker pointed to progress in Solid’s Friedreich’s ataxia program.
- Solid is set to present at the Goldman Sachs healthcare conference on June 8, the next investor event on its calendar.
Solid Biosciences Inc. shares drew fresh focus Friday as the biotech’s gene therapy pipeline kept the stock active. Shares closed at $7.24 Thursday, up about 6%. H.C. Wainwright had raised its price target two days earlier. Trading ranged between $6.87 and $7.50, with volume at about 1.01 million, market data showed.
Timing counts here. Nasdaq’s main hours are 9:30 a.m. to 4:00 p.m. Eastern, and the trading day hadn’t started yet at the dateline. Premarket trading is the early window before the bell, and often sees thin volume, so small trades can swing prices more than later in the day.
H.C. Wainwright lifted its price target on Solid to $25 from $20 and kept a Buy rating. The firm pointed to progress with SGT-212, Solid’s experimental therapy for Friedreich’s ataxia, a rare genetic condition affecting nerves and the heart. A price target signals where analysts think a stock could trade in the next year.
Solid Biosciences said two patients have been given doses in its Phase 1b FALCON trial, an early-stage study focused on safety and dosage. The company said there were no serious adverse events so far and expects to release first clinical data from the study in the second half of 2026.
Solid in May said SGT-212 was well tolerated in two participants as of May 11, and there were no serious adverse events. Solid reported $380.7 million in cash, cash equivalents and available-for-sale securities at March 31. The company said that cash is enough to fund operations into the first half of 2028.
SGT-003 is still at the center for Solid, which is testing the investigational gene therapy in Duchenne muscular dystrophy. The disease causes muscles to waste away and hits boys most. The company began dosing in the Phase 3 IMPACT DUCHENNE trial in May. That late-stage study will track if the treatment is safe and does its job in more patients.
Solid CEO Bo Cumbo said in the quarterly update that the company made “meaningful strides” in early 2026, noting its first Phase 3 Duchenne dosing and winning European orphan-drug status. Chief Medical Officer Gabriel Brooks called the Phase 3 dosing “a critical moment.” Solid Biosciences Inc.
Sarepta Therapeutics’ Elevidys leads in Duchenne gene therapy, but the FDA in November 2025 slapped on a boxed warning for serious liver injury and acute liver failure. The agency also narrowed Elevidys’ use to Duchenne patients 4 and up who can still walk. With that, liver safety and how trials are run have become key issues for new players.
Regenxbio is also in the race. In May, the company put out interim results for RGX-202, its Duchenne gene therapy candidate. Pivotal-dose patients did better than external controls on functional measures at one year. The Phase I/II safety profile stayed favorable, the company said.
Biotech is adding some lift too. The Nasdaq Biotechnology Index was last up 2.32% at 5,941.66. The SPDR S&P Biotech ETF traded $133.42, up around 2.7%. Sector action supports the tape but doesn’t fully explain trading in a clinical-stage name.
Solid Biosciences Inc. is set to present at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, at 4:00 p.m. ET. CEO Bo Cumbo will lead the presentation, the company said. A webcast replay will be available for 90 days.
Risks are hard to miss. Solid has no approved drugs in its referenced programs, and both SGT-003 and SGT-212 are still experimental. Any safety issue, slow trial recruitment, poor efficacy, or stricter FDA approach to accelerated approval could pressure the shares. Solid posted a Q1 net loss of $56.7 million and R&D costs of $46.1 million, so cash burn is a focus as investors wait for trial updates.
